BR9909338A - Aminoguanidinas e alcóxiguanidinas substituìdas com benzamida e sulfonamida como inibidores de proteases - Google Patents
Aminoguanidinas e alcóxiguanidinas substituìdas com benzamida e sulfonamida como inibidores de proteasesInfo
- Publication number
- BR9909338A BR9909338A BR9909338-3A BR9909338A BR9909338A BR 9909338 A BR9909338 A BR 9909338A BR 9909338 A BR9909338 A BR 9909338A BR 9909338 A BR9909338 A BR 9909338A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibiting
- compounds
- formation
- blood
- present
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title abstract 4
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical class NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 title abstract 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title abstract 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 150000003456 sulfonamides Chemical group 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 5
- 230000002401 inhibitory effect Effects 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 108090000190 Thrombin Proteins 0.000 abstract 2
- 230000002785 anti-thrombosis Effects 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000001772 blood platelet Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960004072 thrombin Drugs 0.000 abstract 2
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 150000002357 guanidines Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
"AMINOGUANIDINAS E ALCóXIGUANIDINAS SUBSTITUìDAS COM BENZAMIDA E SULFONAMIDA COMO INIBIDORES DE PROTEASES" A presente invenção se refere a composto de aminoguanidina e de alcóxi guanidina, incluindo os compostos da Fórmula (I), em que X é O ou NH, L é -O- ou SO~ 2~-, e R¹-R^ 4^, R^ 9^-R^ 19^, R^ a^, R^ b^, R^ c^, Y, Z, m e n são descritos na especificação, assim como seus hidratos, solvatos e seus sais aceitáveis do ponto de vista farmacêutico, que inibem as enzimas proteolíticas tais como trombina. Também descritos são processos para a preparação de compostos da Fórmula (I). Alguns destes compostos apresentam atividade anti-trombótica através de uma inibição direta seletiva de trombina, ou são intermediários úteis para a formação de composições que têm atividade anti-trombótica. A presente invenção inclui uma composição para a inibição da perda de plaquetas sang³íneas, a inibição de formação de agregados de plaquetas sang³íneas, inibição de formação de fibrina, inibição de formação de trombos, e inibição de formação de êmbolos em um mamífero. Outros empregos dos compostos da presente invenção são como anti-coagulantes quer embutidos em materiais empregados na fabricação de dispositivos empregados na coleta de sangue, circulação de sangue ou armazenagem de sangue ou fisicamente ligados a eles.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8056898P | 1998-04-03 | 1998-04-03 | |
| US09/283,241 US6344486B1 (en) | 1998-04-03 | 1999-04-01 | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
| PCT/US1999/007420 WO1999051571A1 (en) | 1998-04-03 | 1999-04-05 | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9909338A true BR9909338A (pt) | 2000-12-12 |
Family
ID=26763687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9909338-3A BR9909338A (pt) | 1998-04-03 | 1999-04-05 | Aminoguanidinas e alcóxiguanidinas substituìdas com benzamida e sulfonamida como inibidores de proteases |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6344486B1 (pt) |
| EP (1) | EP1070049B1 (pt) |
| JP (1) | JP2002510673A (pt) |
| KR (1) | KR20010042396A (pt) |
| CN (1) | CN1303365A (pt) |
| AT (1) | ATE270269T1 (pt) |
| AU (1) | AU755805B2 (pt) |
| BR (1) | BR9909338A (pt) |
| CA (1) | CA2326759A1 (pt) |
| DE (1) | DE69918421T2 (pt) |
| EA (1) | EA003461B1 (pt) |
| HU (1) | HUP0102371A3 (pt) |
| IL (1) | IL138799A0 (pt) |
| NO (1) | NO20004871L (pt) |
| NZ (1) | NZ507050A (pt) |
| PL (1) | PL343244A1 (pt) |
| WO (1) | WO1999051571A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
| US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US20060199811A1 (en) * | 1997-07-31 | 2006-09-07 | Pfirrmann Rolf W | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US6344486B1 (en) | 1998-04-03 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
| US6348504B1 (en) * | 1999-03-30 | 2002-02-19 | Richard E. Olson | Oxime ethers as IIb/IIa antagonists |
| US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| KR20030022353A (ko) | 2000-08-04 | 2003-03-15 | 3-디멘져널 파마슈티칼즈 인코오포레이티드 | 사이클릭 옥시구아니딘 프로테아제 저해제 |
| US6486174B2 (en) | 2000-08-07 | 2002-11-26 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| US20020037897A1 (en) * | 2000-08-07 | 2002-03-28 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| UA75093C2 (en) | 2000-10-06 | 2006-03-15 | Dimensional Pharm Inc | Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors |
| AR040126A1 (es) | 2002-05-29 | 2005-03-16 | Glaxo Group Ltd | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento |
| PT1569912E (pt) | 2002-12-03 | 2015-09-15 | Pharmacyclics Llc | Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia |
| US20060194825A1 (en) * | 2002-12-20 | 2006-08-31 | Migenix Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| AU2003300360A1 (en) * | 2002-12-20 | 2004-07-22 | Migenix Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| AU2004201264B2 (en) * | 2003-03-28 | 2009-12-24 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Adhesive Antineoplastic Compositions |
| US7468350B2 (en) | 2004-06-16 | 2008-12-23 | Pneumrx, Inc. | Glue composition for lung volume reduction |
| US7678767B2 (en) | 2004-06-16 | 2010-03-16 | Pneumrx, Inc. | Glue compositions for lung volume reduction |
| CA2570261C (en) | 2004-07-08 | 2014-06-10 | Pneumrx, Inc. | Pleural effusion treatment device, method and material |
| EP2658580A4 (en) * | 2010-12-31 | 2014-07-23 | Corridor Pharmaceuticals Inc | ARGINE STARTER AND USE METHOD |
| US9788539B2 (en) | 2011-05-17 | 2017-10-17 | Velico Medical, Inc. | Platelet protection solution having beta-galactosidase and sialidase inhibitors |
| JP2014515352A (ja) | 2011-05-17 | 2014-06-30 | ベリコ メディカル インコーポレイティッド | シアリダーゼ阻害剤を用いた血小板の保存の改善法 |
| WO2014055988A1 (en) | 2012-10-05 | 2014-04-10 | Velico Medical, Inc. | Platelet additive solution having a beta-galactosidase inhibitor |
| WO2014120886A1 (en) | 2013-01-30 | 2014-08-07 | Velico Medical, Inc. | Platelet additive solution having a self-assembling hydrogel-forming peptide |
| CN104530113A (zh) * | 2014-12-22 | 2015-04-22 | 上海树农化工有限公司 | 邻氟苯甲酸类化合物及其制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4652440A (en) | 1984-05-03 | 1987-03-24 | Paik Chang H | Method of stably radiolabeling antibodies with technetium and rhenium |
| GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| DE3835815A1 (de) * | 1988-10-21 | 1990-04-26 | Hoechst Ag | Neue isohirudine |
| EP0604022A1 (en) | 1992-12-22 | 1994-06-29 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method for its manufacture |
| GB9318637D0 (en) | 1993-09-08 | 1993-10-27 | Ferring Res Ltd | Enzyme inhibitors |
| US6087479A (en) | 1993-09-17 | 2000-07-11 | Nitromed, Inc. | Localized use of nitric oxide-adducts to prevent internal tissue damage |
| US5466811A (en) | 1994-07-18 | 1995-11-14 | Merck & Co., Inc. | Dioxolenylmethyl carbamates pro moieties for amine drugs |
| US5643580A (en) | 1994-10-17 | 1997-07-01 | Surface Genesis, Inc. | Biocompatible coating, medical device using the same and methods |
| EP1477132A3 (en) | 1994-10-17 | 2009-09-09 | Kabushikikaisha Igaki Iryo Sekkei | Drug-releasing stent |
| US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
| DE19514104C2 (de) | 1995-04-13 | 1997-05-28 | Behringwerke Ag | Beschichtung für in den Blutstrom oder in das Gewebe des menschlichen Körpers einbringbares Biomaterial |
| IL123802A0 (en) | 1995-09-29 | 1998-10-30 | 3-Dimensional Pharma Inc | Guanidino protease inhibitors |
| US5792769A (en) | 1995-09-29 | 1998-08-11 | 3-Dimensional Pharmaceuticals, Inc. | Guanidino protease inhibitors |
| GB9525620D0 (en) | 1995-12-15 | 1996-02-14 | Glaxo Group Ltd | Chemical compounds |
| DE69736777T2 (de) | 1996-03-29 | 2007-08-23 | Ortho-Mcneil Pharmaceutical, Inc. | Amidinohydrazone als protease-inhibitoren |
| TW499412B (en) | 1996-11-26 | 2002-08-21 | Dimensional Pharm Inc | Aminoguanidines and alkoxyguanidines as protease inhibitors |
| US6344486B1 (en) | 1998-04-03 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
-
1999
- 1999-04-01 US US09/283,241 patent/US6344486B1/en not_active Expired - Lifetime
- 1999-04-05 EA EA200001024A patent/EA003461B1/ru not_active IP Right Cessation
- 1999-04-05 WO PCT/US1999/007420 patent/WO1999051571A1/en active IP Right Grant
- 1999-04-05 JP JP2000542293A patent/JP2002510673A/ja active Pending
- 1999-04-05 EP EP99914339A patent/EP1070049B1/en not_active Expired - Lifetime
- 1999-04-05 HU HU0102371A patent/HUP0102371A3/hu unknown
- 1999-04-05 AT AT99914339T patent/ATE270269T1/de not_active IP Right Cessation
- 1999-04-05 PL PL99343244A patent/PL343244A1/xx not_active Application Discontinuation
- 1999-04-05 BR BR9909338-3A patent/BR9909338A/pt not_active IP Right Cessation
- 1999-04-05 AU AU32210/99A patent/AU755805B2/en not_active Ceased
- 1999-04-05 IL IL13879999A patent/IL138799A0/xx unknown
- 1999-04-05 NZ NZ507050A patent/NZ507050A/xx unknown
- 1999-04-05 CA CA002326759A patent/CA2326759A1/en not_active Abandoned
- 1999-04-05 KR KR1020007010967A patent/KR20010042396A/ko not_active Application Discontinuation
- 1999-04-05 DE DE69918421T patent/DE69918421T2/de not_active Expired - Fee Related
- 1999-04-05 CN CN99806626A patent/CN1303365A/zh active Pending
-
2000
- 2000-09-28 NO NO20004871A patent/NO20004871L/no not_active Application Discontinuation
-
2001
- 2001-02-28 US US09/796,319 patent/US6344466B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NZ507050A (en) | 2003-06-30 |
| AU3221099A (en) | 1999-10-25 |
| HUP0102371A2 (hu) | 2001-12-28 |
| NO20004871D0 (no) | 2000-09-28 |
| ATE270269T1 (de) | 2004-07-15 |
| CA2326759A1 (en) | 1999-10-14 |
| EP1070049A1 (en) | 2001-01-24 |
| US6344486B1 (en) | 2002-02-05 |
| AU755805B2 (en) | 2002-12-19 |
| KR20010042396A (ko) | 2001-05-25 |
| EA003461B1 (ru) | 2003-06-26 |
| NO20004871L (no) | 2000-11-30 |
| JP2002510673A (ja) | 2002-04-09 |
| US6344466B2 (en) | 2002-02-05 |
| IL138799A0 (en) | 2001-10-31 |
| CN1303365A (zh) | 2001-07-11 |
| WO1999051571A1 (en) | 1999-10-14 |
| DE69918421D1 (de) | 2004-08-05 |
| HUP0102371A3 (en) | 2002-11-28 |
| DE69918421T2 (de) | 2005-07-21 |
| US20010031870A1 (en) | 2001-10-18 |
| PL343244A1 (en) | 2001-07-30 |
| EA200001024A1 (ru) | 2001-04-23 |
| EP1070049B1 (en) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9909338A (pt) | Aminoguanidinas e alcóxiguanidinas substituìdas com benzamida e sulfonamida como inibidores de proteases | |
| BR9713328A (pt) | Aminoguanidinas e alcoxiguanidinas como inibidores de proteases. | |
| BR9815325A (pt) | Heteroaril, aminoguanidinas e alcóxiguanidinas eseu uso como inibidores da protease | |
| BR9911100A (pt) | Inibidores de pirazinona protease | |
| DK1140918T3 (da) | Thrombininhibitorer | |
| BR9810177A (pt) | Composto, formulação farmacêutica, uso de um composto, e, processos para tratamento de uma condição onde a inibição da trombina é requerida e para a preparação de compostos | |
| CA2186497A1 (en) | Factor xa inhibitors | |
| BR0309671A (pt) | ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease | |
| SE9602263D0 (sv) | New amino acid derivatives | |
| DE69902754T2 (de) | Heteroaryl-amidinen,-methylamidinen und -guanidinen als protease inhibitoren, insbesondere als urokinase inhibitoren | |
| BR9813410A (pt) | Composto, formulação farmacêutica, uso de um composto, e, processos de tratamento de uma condição, em que a inibição de trombina é requerida ou desejada, e para a preparação de um composto. | |
| TR199801569T2 (xx) | Serin proteaz inhibit�rleri. | |
| DE69912279D1 (de) | 5-ht1f agonisten | |
| DK1324981T3 (da) | Aminopyridinyl-, aminoguanidinyl- og alkoxyguanidinylsubstituerede phenylacetamider som proteaseinhibitorer | |
| ATE338030T1 (de) | Amidine-inhibitoren der serine-proteasen | |
| Viappiani et al. | The role of matrix metalloproteinase inhibitors in ischemia-reperfusion injury in the liver | |
| ATE330601T1 (de) | Sulfonamide als matrix-metalloproteinase inhibitoren | |
| EA200301116A1 (ru) | Гидроксаматы ароматических сульфонов и их применение в качестве ингибиторов протеаз | |
| ATE338746T1 (de) | Harnstoffverbindungen mit antiproteolytischer wirkung | |
| NO20012914L (no) | Nye amidinoderivater og deres anvendelse som trombininhibitorer | |
| BR0110794A (pt) | Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, método de tratamento de uma condição onde a inibição de trombina é requerida | |
| Pâques et al. | Comparative study on the in vitro effectiveness of antithrombotic agents | |
| BR9813719A (pt) | Agentes terapêuticos | |
| DE60005351D1 (de) | Heteroaryl protease inhibitoren und diagnostische bilderzeugungsmittel | |
| WO1999063090A3 (en) | Protease inhibitor peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007. |